Holen Sie sich die Stockscreener-App
27.38
6.44%
1.81
Handel nachbörslich:
27.38
Schlusskurs vom Vortag:
$25.57
Offen:
$25.29
24-Stunden-Volumen:
617.32K
Relative Volume:
2.56
Marktkapitalisierung:
$453.53M
Einnahmen:
$102.48M
Nettoeinkommen (Verlust:
$-191.09M
KGV:
-1.8987
EPS:
-14.4203
Netto-Cashflow:
$-178.93M
1W Leistung:
-14.06%
1M Leistung:
-18.34%
6M Leistung:
+207.08%
1J Leistung:
+195.83%
1-Tages-Spanne:
$25.10
$27.93
1-Wochen-Bereich:
$25.10
$32.72
52-Wochen-Spanne:
$6.736
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
27.37 | 423.71M | 102.48M | -191.09M | -178.93M | -14.42 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-24 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma CEO unveils expanding ADC pipeline and key cancer partnerships - Traders Union
Sutro Biopharma (STRO) price target increased by 1,325.54% to 39.05 - MSN
Sutro Biopharma (STRO) Consolidates Near Resistance: Biotech Stock Shows Modest GainsSocial Trading Insights - Newser
Sutro Biopharma (STRO) Sees Minor Dip, Holds Above Key SupportWyckoff Accumulation - Newser
STRO SEC FilingsSutro Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
US$47.10That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results - Yahoo Finance
Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows - Moomoo
STRO Maintained by HC Wainwright & Co. -- Price Target Raised to $50 - GuruFocus
STRO Upgraded by Wedbush -- Price Target Raised to $60 - GuruFocus
Is Sutro Biopharma (STRO) 189.6% Overvalued After Q1 2026? EPS b - GuruFocus
Sutro Biopharma (STRO) affiliates disclose 1.06M shares; ownership details - Stock Titan
Kynam Capital reports 5.27% stake in Sutro Biopharma (NASDAQ: STRO) - Stock Titan
STRO Maintained by Leerink Partners -- Price Target Raised to $4 - GuruFocus
Sutro Biopharma Shares Rise After Q1 Loss Narrows - marketscreener.com
Gemini Space posts upbeat Q1 results, joins Figma, Sutro Biopharma and other big stocks moving higher on Friday - MSN
Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22 - Moomoo
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday - Benzinga
Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside - TradingView
Sutro Biopharma (STRO) Q1 Revenue Surpasses Expectations - GuruFocus
Sutro Biopharma Q1 Loss Narrows, Revenue Declines - Moomoo
Sutro Biopharma (NASDAQ: STRO) narrows Q1 loss and boosts cash with $110M share sale - Stock Titan
Sutro Biopharma releases first quarter financials and updates business outlook - Traders Union
Net loss narrows as Sutro Biopharma (NASDAQ: STRO) boosts cash into 2028 - Stock Titan
Sutro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Affinity Asset Advisors (NASDAQ: STRO) discloses 6.5% stake - Stock Titan
Cancer-drug maker Sutro projects cash runway into 2028 as ADC pipeline advances - Stock Titan
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights - marketscreener.com
Wedbush Raises Price Target on Sutro Biopharma to $22 From $10, Keeps Neutral Rating - Moomoo
MSN Money - MSN
Certain Warrants of Sutro Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 12-MAY-2026. - marketscreener.com
Certain Options of Sutro Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 12-MAY-2026. - marketscreener.com
How sustainable is Sutro Biopharma (STRO) profit margins? (Runs Up) 2026-05-08High Attention Stocks - newser.com
Is Sutro Biopharma (STRO) building a durable competitive moat? (+5.68%) 2026-05-08Seasonality Effect - Newser
Sutro Biopharma (STRO) Eps Diluted (TTM) - Zacks Investment Research
Sutro Biopharma (STRO) to Release Earnings on Thursday - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial - MarketBeat
Sutro Biopharma Inc expected to post a loss of $3.77 a shareEarnings Preview - TradingView
STRO Sutro Biopharma slips 2.81% as its Q4 2025 loss lands 19.4% below analyst consensus estimates.Credit Risk - newser.com
Sutro Biopharma (NASDAQ:STRO) Upgraded at Lifesci Capital - MarketBeat
Citizens Raises Sutro Biopharma Price Target to 41 Dollars - HarianBasis.co
Point72 group (NASDAQ: STRO) reports 5.7% stake — 946,829 shares - Stock Titan
Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program - Insider Monkey
Mizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendation - MSN
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell - Seeking Alpha
This Palantir Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):